Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.

Abstract

Current treatments of high-grade lymphoma often have curative potential, but unfortunately many patients relapse and develop therapeutic resistance. Thus, there remains a need for novel therapeutics that can target the residual cancer cells whose phenotypes are distinct from the bulk tumor and that are capable of reforming tumors from very few cells. Oncolytic viruses offer an approach to destroy tumors by multiple mechanisms, but they cannot effectively reach residual disease or micrometastases, especially within the lymphatic system. To address these limitations, we have generated immune cells infected with oncolytic viruses as a therapeutic strategy that can combine effective cellular delivery with synergistic tumor killing. In this study, we tested this approach against minimal disease states of lymphomas characterized by the persistence of cancer cells that display stem cell-like properties and resistance to conventional therapies. We found that the immune cells were capable of trafficking to and targeting residual cancer cells. The combination biotherapy used prevented relapse by creating a long-term, disease-free state, with acquired immunity to the tumor functioning as an essential mediator of this effect. Immune components necessary for this acquired immunity were identified. We further demonstrated that the dual biotherapy could be applied before or after conventional therapy. Our approach offers a potentially powerful new way to clear residual cancer cells, showing how restoring immune surveillance is critical for maintenance of a disease-free state.

• Authors: Christopher H Contag, Rachel Sikorski, Robert S Negrin, Tobi Schmidt, Alice C Fan, Pavan Bachireddy, Dean W Felsher, Steve H Thorne
• Journal: Cancer research (Cancer Res) Vol. 70 Issue 23 Pg. 9837-45 (Dec 01 2010) ISSN: 1538-7445 [Electronic] United States
• PMID: 20935221 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Myc protein, mouse
• Proto-Oncogene Proteins c-myc

Topics

• Animals
• Cell- and Tissue-Based Therapy (methods)
• Humans
• Lymphoma (immunology, pathology, therapy)
• Mice
• Mice, Inbred BALB C
• Mice, Inbred NOD
• Mice, SCID
• Mice, Transgenic
• Natural Killer T-Cells (immunology, metabolism)
• Neoplasm, Residual (immunology, pathology, prevention & control)
• Oncolytic Virotherapy (methods)
• Oncolytic Viruses (genetics, immunology)
• Proto-Oncogene Proteins c-myc (genetics, immunology)
• Treatment Outcome
• Tumor Cells, Cultured